Anlongmed Fund

investment firm

About

Anlongmed Fund is focused on early-stage investments in the life sciences and healthcare-related fields.

Details

Industries
Financial Services
Operating Status
Active
Legal Name
Anlong Investment Management Ltd
Also Known As
安龙基金
Investor Type
Venture Capital

AnlongMed is a venture capital fund focuses on early stage life science and healthcare sectors. It is managed by a team led by Dr. Adam Zhao Chunlin, a veteran in life science with 30 years of experience, along with professionals with MNC, R&D, clinical, entrepreneurial and investment experience in both U.S. and China. The fund is anchored by Chinese Academy of Sciences. With extensive experience and connections from Chinese Academy of Sciences, Tsinghua University, Peking Union Medical College, and Bayhelix Group, AnlongMed strives to help entrepreneurs to start a venture in life science and healthcare in China. The fund has invested 22 firms from its first phase, including Netvation, a joint initiative toward new drug development between Chinese Academy of Science and Pfizer, Inc, 4 companies founded together with entrepreneurs across life science, biopharmaceutical, medical devices, and healthcare services.

Investments

Number of Investments
Number of Lead Investments
9
3
Anlongmed Fund has made 9 investments. Their most recent investment was on Jan 20, 2021, when Skynor Medical raised 0.
Date Company Name
Round Money Raised Industry Lead Investor
Jan 20, 2021 Skynor Medical
Series B Health Care
Jun 23, 2020 Sophonix
Series B ¥100M Biotechnology
Aug 1, 2019 Zhenzhun Biotech
Series A Biotechnology Yes
Series A $18.50M Biotechnology
May 8, 2018 Jun Hui Biotech
Seed Health Care Yes

Exits

Anlongmed Fund has had 1 exits. Anlongmed Fund most notable exits include Connect Biopharmaceuticals

Date Company Name Exit Type Industry
Mar 18, 2021 Connect Biopharmaceuticals IPO Biotechnology Detail